Editas Medicine to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Editas Medicine (Nasdaq: EDIT) announced that management will participate in two September investor conferences: the Wells Fargo Healthcare Conference on September 8, 2026 at 4:30 p.m. ET in Boston, and the Cantor Global Healthcare Conference on September 10, 2026 at 3:55 p.m. ET in New York.

Both appearances will be fireside chats, with live webcasts and 30-day replays available via the company’s investor relations website.

News Market Reaction – EDIT

+0.33%

8 alerts

+0.33% Session close to close

$497.68M Market Cap

0.9x Rel. Volume

In the Sep 1 session, EDIT gained 0.33%, reflecting a mild positive market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September:

• Wells Fargo Healthcare Conference
  Format: Fireside Chat
  Date: Tuesday, September 8
  Time: 4:30 p.m. ET
  Location: Boston, MA

• 2026 Cantor Global Healthcare Conference
  Format: Fireside Chat
  Date: Thursday, September 10
  Time: 3:55 p.m. ET
  Location: New York, NY
  
  

To access the live webcast of Editas Medicine’s Fireside Chats, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.

About Editas Medicine 
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. 

Investor and Media Contacts: 
ir@editasmed.com 
media@editasmed.com  

FAQ

When will Editas Medicine (EDIT) present at the 2026 Wells Fargo Healthcare Conference?

Editas Medicine will participate in a fireside chat at the Wells Fargo Healthcare Conference on Tuesday, September 8, 2026 at 4:30 p.m. ET. According to Editas Medicine, the event will take place in Boston, Massachusetts and be accessible via live webcast on its investor website.

When is Editas Medicine’s (EDIT) 2026 Cantor Global Healthcare Conference fireside chat?

Editas Medicine’s fireside chat at the 2026 Cantor Global Healthcare Conference is scheduled for Thursday, September 10, 2026 at 3:55 p.m. ET. According to Editas Medicine, this presentation will occur in New York, New York and be streamed live through the company’s investor relations website.

How can investors listen to Editas Medicine’s (EDIT) September 2026 conference webcasts?

Investors can access Editas Medicine’s September 2026 conference webcasts by visiting the “Investors” section of www.editasmedicine.com. According to Editas Medicine, both fireside chats will be streamed live and are designed to give shareholders direct access to management’s presentations.

Will replays of Editas Medicine’s (EDIT) September 2026 investor conference presentations be available?

Yes, replays will be available. According to Editas Medicine, an archived replay of each September 2026 fireside chat will be accessible on its website for approximately 30 days following each event, allowing investors to review management’s remarks after the live sessions.